GlassScriptPhysician profile
Emily Runyan
NPI 1285894709
$2,058.50
in general payments reported to CMS, 2019-2025
21 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $77.18 · 2024: $776 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,058.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $315.19 | 2025 | Invega Sustenna, Spravato |
| Axsome Therapeutics, INC. | $273.76 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $248.97 | 2024 | Fanapt |
| Astrazeneca Pharmaceuticals LP | $243.23 | 2023-2025 | Airsupra, Breztri, Tezspire |
| Abbvie INC. | $193.94 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $187.86 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $137.58 | 2025 | Austedo Xr, Uzedy |
| Novo Nordisk INC | $103.07 | 2024-2025 | Ozempic, Rybelsus |
| Ironshore Pharmaceuticals INC. | $101.00 | 2024 | |
| Glaxosmithkline, LLC. | $35.42 | 2023-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Sanofi Pasteur INC. | $31.01 | 2025 | |
| Organogenesis INC. | $23.49 | 2024 | |
| Merck Sharp & Dohme LLC | $23.39 | 2025 | Gardasil 9, Enflonsia, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.84 | 2023 | Ofev |
| E.R. Squibb & Sons, L.L.C. | $19.99 | 2025 | Sotyktu |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $19.52 | 2024 | Collagenase Santyl |
| Pfizer INC. | $19.08 | 2024 | |
| Mimedx Group, INC. | $17.53 | 2024 | |
| Seqirus USA INC | $15.91 | 2025 | Flucelvax, Fluad |
| Lilly USA, LLC | $14.71 | 2025 | Mounjaro |
| Grifols USA, LLC | $13.01 | 2023 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Runyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.